Los Angeles Capital Management LLC Purchases 6,484 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Los Angeles Capital Management LLC lifted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 46.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,474 shares of the biopharmaceutical company’s stock after buying an additional 6,484 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Amicus Therapeutics were worth $219,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Hazlett Burt & Watson Inc. boosted its stake in Amicus Therapeutics by 156.9% during the third quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 1,569 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,831 shares during the last quarter. Arcadia Investment Management Corp MI bought a new stake in shares of Amicus Therapeutics in the 3rd quarter worth approximately $32,000. Headlands Technologies LLC purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter worth approximately $89,000. Finally, Sage Capital Advisors llc bought a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $103,000.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total value of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at $9,398,532.40. This represents a 0.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 30,401 shares of company stock valued at $352,038. Insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on FOLD. Guggenheim increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Jefferies Financial Group began coverage on shares of Amicus Therapeutics in a research note on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Bank of America upped their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $17.63.

Amicus Therapeutics Stock Performance

Shares of FOLD opened at $9.66 on Tuesday. The firm has a market capitalization of $2.89 billion, a P/E ratio of -28.41 and a beta of 0.68. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The business has a fifty day moving average of $10.96 and a 200 day moving average of $10.61.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.